



UNITED STATES DEPARTMENT OF COMMERCE
Patent and Trademark Office
Address: COMMISSIONER OF PATENTS AND TRADEMARKS
Washington, D.C. 20231

SERIAL NUMBER	FILING DATE	FIRST NAMED APPLICANT		ATTORNEY DOCKETT NO.
				EXAMINER
			L	
			ART UNIT	PAPER NUMBER
				34
		EXAMINER INTERVIEW SUMMARY REC	DATE MAILED:	
All participants (applicar	nt, applicant's represent	ative, PTO personnel):	1	•
(1) C. E	more	(3)	Smith	
	lata			
(2)	124/96	(4)	· · · · · · ·	
Date of Interview				
		ven to applicant applicant's representative).		
Exhibit snown or demon	istration conducted: \Box	Yes No. If yes, brief description:		
Claims discussed:	All Cl	All cited prior ar	- d ,	
Description of the gener Submitted Wercome agreen	l propose	greed to if an agreement was reached, or any other or a mand mand which ejections, if submitted with respect to	omments: Apply would a hed, Th	ppear to eve was no rejection
of the c	Laims	•		
		i the amendments, if available, which the examiner agents which would render the claims allowable is availal		
		de a separate record of the substance of the interview	-	,
WAIVED AND MUST IN	ICLUDE THE SUBSTAI	to indicate to the contrary, A FORMAL WRITTEN RE: NCE OF THE INTERVIEW (e.g., items 1-7 on the reve given one month from this interview date to provide a	erse side of this form).	If a response to the last Office
requirements th	nat may be present in the rements of the last Office.	ry above (including any attachments) reflects a complete last Office action, and since the claims are now allow action. Applicant is not relieved from providing a se	wable, this completed f	orm is considered to fulfill the

PROPOSED CLAIMS FOR UMMC91-03A (U.S.S.N. 08/009,833)

Cancel Claims 1, 2, 4, 7-14, 17-18, and 22-24.

Claims 19-21 are unchanged:

- 19. A method of immunizing a vertebrate against influenza virus, said method comprising administering to a vertebrate a DNA transcription unit comprising DNA encoding an influenza virus antigen operatively linked to a promoter region, thereby eliciting a humoral immune response, a cell-mediated immune response or both, against the influenza virus antigen, whereby the vertebrate is protected from disease caused by influenza virus.
- 20. The method of Claim 19, wherein the influenza virus antigen is hemagglutinin.
- 21. The method of Claim 20, wherein the hemagglutinin is subtype H1 or H7.

NEW CLAIMS: Previous claims 2 and 7-10 are cancelled and rewritten as dependent on Claim 19.

- 25. The method of Claim 19, wherein the DNA transcription unit is of nonretroviral origin.
- 26. The method of Claim 19, wherein the vertebrate is a mammal.
- 27. The method of Claim 26, wherein the mammal is a human.
- 28. The method of Claim 19, wherein the DNA transcription unit, in a physiologically acceptable carrier, is administered to a vertebrate through a route of administration chosen from the group consisting of intranasal, intravenous, intramuscular, intraperitoneal, intradermal and subcutaneous.

907